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Abstract
Acquired resistance of cancer cells to various chemotherapeutic agents is known as multidrug resistance, and remains a
critical factor in the success of cancer treatment. It is necessary to develop the inhibitors for multidrug resistance. The aim of
this study was to examine the effects of eight a-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and
transport. Previously established HeLa/SN100 cells, which overexpress ABCG2/BCRP but not ABCB1/MDR1, were used. The
effects of the antagonists on sensitivity to mitoxantrone and the transport activity of Hoehst33342, both substrates for
ABCG2/BCRP, were evaluated using the WST-1 assay and cellular kinetics, respectively. ABCG2/BCRP mRNA expression and
the cell cycle were also examined by real-time RT-PCR and flow cytometry, respectively. Sensitivity to mitoxantrone was
reversed by the a-adrenoceptor antagonists in a concentration-dependent manner, although such effects were also found
in the parental HeLa cells. Levels of ABCG2/BCRP mRNA expression were not influenced by the antagonists. The transport
activity of Hoechst33342 was decreased by doxazosin and prazosin, but unaffected by the other antagonists. In addition,
doxazosin and prazosin increased the proportion of S phase cells in the cultures treated with mitoxantrone, whereas the
other a-adrenoceptor antagonists increased the percentage of cells in G2/M phase. These findings suggested that doxazosin
and prazosin reversed resistance mainly by inhibiting ABCG2/BCRP-mediated transport, but the others affected sensitivity to
mitoxantrone via a different mechanism.
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Introduction
Acquired resistance of cancer cells to various chemotherapeutic
agents is known as multidrug resistance (MDR), and remains a
critical factor in the success of cancer treatment [1]. A key
mechanism for MDR is enhanced cellular efflux of chemothera-
peutic agents due to overexpression of ATP-Binding Cassette
(ABC) transporters, for example ABCB1/P-glycoprotein (MDR1),
the ABCC/multidrug resistance protein (MRP) family, and
ABCG2/breast cancer resistance protein (BCRP) [1–3]. Recent
studies demonstrated that ABCG2/BCRP was highly abundant in
various types of solid and hematological tumors [4]. In addition, a
strong correlation between ABCG2/BCRP expression and the
rate of response to chemotherapy or survival was found in tumor
samples from 72 non-small cell lung cancer patients [5].
Therefore, ABCG2/BCRP as well as MDR1/ABCB1 plays a
significant role in drug resistance, and inhibitors for ABCG2/
BCRP may enhance the outcome of cancer chemotherapy.
a-Adrenoceptor antagonists are used widely to treat hyperten-
sion, dysuria with prostatic hyperplasia, and migraine headaches
[6,7]. In addition, a-adrenoceptor antagonists used for benign
prostatic hyperplasia have shown growth inhibitory effects on
human prostate cancer cells [6–9]. Moreover, one antagonist,
prazosin, was suggested to be a substrate for ABCG2/BCRP
[10,11]. However, little information is available about the effects of
other a-adrenoceptor antagonists on ABCG2/BCRP.
Previously, we have established HeLa/SN100 cells, isolated
from HeLa cells by continuous exposure to SN-38, an active
metabolite of irinotecan hydrochloride [12]. The HeLa/SN100
cells showed a decrease in sensitivity to not only SN-38 but also
other chemotherapeutic agents as compared with HeLa cells, and
overexpressed ABCG2/BCRP but not MDR1/ABCB1 [12]. In
the present study, the effects of eight a-adrenoceptor antagonists
(Figure 1) on ABCG2/BCRP-mediated resistance and transport
were examined in the HeLa/SN100 cells.
Results
Effects of a-adrenoceptor antagonists on sensitivity to
mitoxantrone
Table 1 shows the sensitivity to mitoxantrone, a substrate for
ABCG2/BCRP, of HeLa and HeLa/SN100 cells in the presence
of a-adrenoceptor antagonists. The IC50 values for mitoxantrone
in HeLa cells decreased. Those in HeLa/SN100 cells exhibited a
dose-dependent decrease, except for terazosin. For the cytotoxicity
itself, the maximum concentration of ergot alkaloids used was
100 nM.
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mRNA expression
The level of ABCG2/BCRP mRNA was examined in HeLa/
SN100 cells cultured with or without a-adrenoceptor antagonists
(Figure 2). The level was not influenced by any of the
antagonists.
Effects of a-adrenoceptor antagonists on accumulation
and efflux of Hoechst33342
To examine whether sensitivity to mitoxantrone depends on the
activity of ABCG2/BCRP, the accumulation and efflux of
Hoechst33342, a substrate for ABCG2/BCRP, in HeLa and
HeLa/SN100 cells were evaluated in the absence or presence of a-
adrenoceptor antagonists.
Fluorescence micrographs revealed less accumulation in HeLa/
SN100 cells than in HeLa cells (Figure 3). The decrease was
reversed by doxazosin and prazosin, but the other a-adrenoceptor
antagonists had no remarkable effect.
The quantitative analysis of the transport of Hoechst33342
indicated that the accumulation of Hoechst33342 in HeLa/SN100
cells was increased significantly by 10 mM of doxazosin or prazosin
(Figure 4). However, the other a-adrenoceptor antagonists had no
effect at any concentration. In addition, the efflux of
Hoechst33342 from HeLa/SN100 cells reverted to the level for
HeLa cells in the presence of 10 mM doxazosin or prazosin, but
was not affected by the other antagonists (Figure 5).
Effects of a-adrenoceptor antagonists on the cell cycle of
HeLa/SN100 cells treated with mitoxantrone
The cell cycle of HeLa/SN100 cells was analyzed to explore the
mechanism by which a-adrenoceptor antagonists reverse resis-
tance to mitoxantrone. Exposure to mitoxantrone for 8 h resulted
in 46.2% of cells in G0/G1 phase, 37.6% in S phase, and 16.2% in
G2/M phase (Table 2). Concomitant administration of doxazosin,
terazosin, and prazosin tended to increase the number of cells in S
phase, comparable to the findings in HeLa cells treated with
Figure 1. Chemical structure of a-adrenoceptor antagonists used.
doi:10.1371/journal.pone.0030697.g001
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naftopidil, and urapidil, the distribution of G2/M phase cells
increased. Dihydroergotamine and ergotamine did not affect the
cell cycle profile in either cell type.
Discussion
a-adrenoceptor antagonists have been reported to inhibit
growth and induce apoptosis in malignant prostatic cells [13–
17]. However, little is known about how they affect the cytotoxicity
of chemotherapeutic agents. In addition, little information is
available about the effects of a-adrenoceptor antagonists on
ABCG2/BCRP, although prazosin was reported to be a substrate
for ABCG2/BCRP.
In the present study, the sensitivity to mitoxantrone in HeLa/
SN100 cells was reversed by a-adrenoceptor antagonists in a
concentration-dependent manner (Table 1). In addition, such
effects were found in HeLa cells with a spontaneous expression of
ABCG2/BCRP [12], implying that ABCG2/BCRP-mediated
transport also take place in HeLa cells. This was supported by
the findings that the accumulation of Hoechst33342 in HeLa cells
increased by doxazosin and prazosin (data not shown). However,
levels of ABCG2/BCRP mRNA were not influenced (Figure 2),
suggesting that a-adrenoceptor antagonists affect the function but
not expression of ABCG2/BCRP.
Therefore, the effects of quinazoline-based a-adrenoceptor
antagonists (quinazoline derivatives), i.e, doxazosin, prazosin,
and terazosin, on the function of ABCG2/BCRP were examined.
The transport activity of Hoechst33342 was decreased by
doxazosin or prazosin, but not terazosin (Figures 3–5). Doxazosin
and prazosin also increased the proportion of S phase cells among
HeLa/SN100 cells (Table 2), suggesting an acceleration of the
actions of mitoxantrone, i.e., S phase arrest. However, terazosin
did not affect the cell cycle. These findings suggested that both
doxazosin and prazosin reversed the resistance to mitoxantrone via
the inhibition of ABCG2/BCRP-mediated transport, resulting in
an acceleration of the cell cycle’s arrest by mitoxantrone. In
addition, terazosin little affected the function of ABCG2/BCRP,
and this was supported by the absence of an effect on the cell cycle.
Doxazosin, prazosin, and terazosin have the same chemical
structure, carbonylpiperazino-dimethoxyquinazoline, but different
side chains, i.e., benzodioxane, furan, and oxofuran, respectively.
However, the three agents have similar characteristics. The reason
why only terazosin did not affect ABCG2/BCRP remains unclear,
and requires further study.
The other a-adrenoceptor antagonists except for the quinazo-
line derivatives did not affect ABCG2/BCRP-mediated transport
or expression (Figures 2–5), but most of them showed the reversing
effects (Table 1), suggesting that they enhance sensitivity to
mitoxantrone via another pathway. However, these pathways
remain unclear, but the followings may be considered.
Tolazoline, naftopidil, and urapidil increased the proportion of
cells in the G2/M phase, whereas the ergot alkaloid had no effect
(Table 2). These findings suggested that tolazoline, naftopidil, and
urapidil sensitized cells to mitoxantrone via a pathway independent
of transport inhibition, and their actions on the cell cycle may be
involved in the enhancement of sensitivity to mitoxantrone.
Naftopidil was recently suggested to inhibit the growth of human
prostate cancer cells by inducing apoptosis through G1 arrest
[18,19]. The present findings may conflict with these previous
reports [18,19], but could be associated with novel mechanisms of
cell cycle arrest by naftopidil. In the case of the ergot alkaloid, the
activation of caspase-3 may contribute to the enhancement of
sensitivity to mitoxantrone, since the ergot alkaloid was reported to
activate caspase-3 [20]. The pattern of cell death, i.e. necrosis or
apoptosis, after treatment with mitoxantrone was also reported to
differ depending on the type of cell [21]. The present findings may
represent the combined effects of mitoxantrone and the ergot
alkaloid activating caspase-3, but it is necessary to examine the
pattern of cell death after treatment with mitoxantrone in HeLa/
SN100 cells.
Stimulation of the a1-adrenoceptor was also reported to induce
cell proliferation and increase DNA synthesis in various types of
cells [22,23]. Sensitivity to mitoxantrone was enhanced by a-
adrenoceptor antagonists in not only HeLa/SN100 cells but also
HeLa cells. This may be achieved in part by blocking the
stimulation of the a1-adrenoceptor.
The overlap of substrates and inhibitors between ABCB1/P-
glycoprotein and cytochrome P450 3A4 is well established [24].
On the other hand, doxazosin was reported to be a more potent
inhibitor for ABCB1/P-glycoprotein than prazosin [25]. This
trend was also observed in the present study using ABCG2/
BCRP-overexpressing cells, suggesting an overlap of substrates or
inhibitors between ABCG2/BCRP and ABCB1/P-glycoprotein.
The present findings supported the previous report [26].
Table 1. IC50 values for mitoxantrone in HeLa and HeLa/
SN100 cells in the presence of a-adrenoceptor antagonists.
HeLa cells HeLa/SN100 cells
IC50 (nM) R.S. IC50 (nM) R.S.
Control 10.461.95 – 284626.6 –
Doxazosin 0.1 mM1 2 . 1 60.82 0.99 124610.7* 2.40
1 mM 6.5160.64 1.84 64.067.85** 4.64
10 mM 0.7460.04** 16.1 7.5761.33** 39.3
Prazosin 0.1 mM2 0 . 1 61.95* 0.60 346666.2 0.86
1 mM1 1 . 9 60.98 1.00 297646.7 1.00
10 mM 3.3260.91 3.61 40.165.79** 7.39
Terazosin 0.1 mM1 4 . 8 61.46 0.81 331628.8 0.90
1 mM1 8 . 8 60.50* 0.64 384661.5 0.77
10 mM 4.6661.44 2.57 339647.4 0.88
Tolazoline 0.1 mM 6.7760.58 1.77 244640.9 1.22
1 mM 1.5960.55* 7.56 193658.6 1.54
10 mM 2.4560.45* 4.90 45.766.46** 6.51
Naftopidil 0.1 mM 9.4263.17 1.27 15267.13 1.95
1 mM 3.6560.81 3.29 136614.0* 2.19
10 mM 2.0760.28* 5.79 47.867.32** 6.22
Urapidil 0.1 mM 2.9961.12* 4.00 12767.82* 2.34
1 mM 4.0760.92 2.95 13867.83 2.15
10 mM 2.1960.34* 5.48 52.160.85** 5.70
Dihydroergotamine 1 nM 6.7161.26 1.79 271646.6 1.10
10 nM 6.0762.11 1.98 186614.8 1.60
100 nM 5.2361.26 2.29 79.8615.4** 3.73
Ergotamine 1 nM 10.962.63 1.10 213647.4 1.39
10 nM 3.0361.40 3.96 261637.4 1.14
100 nM 1.0360.54* 11.6 52.168.83** 5.70
Each value shows the mean 6 S.E. (n=4).
Relative sensitivity: the ratio of IC50 values for mitoxantrone in the control
divided by that in the groups treated with a-adrenoceptor antagonists.
*and**: significantly different from the respective control at p,0.05 and
p,0.01, respectively.
doi:10.1371/journal.pone.0030697.t001
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reversed the resistance mainly via inhibition of ABCG2/BCRP-
mediated transport, but the others, at least partly, affected
sensitivity to mitoxantrone by acting on the cell cycle.
Materials and Methods
Chemicals
7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite
of irinotecan hydrochloride, was a gift from Yakult Honsha Co.,
Ltd. (Tokyo, Japan). Doxazosin mesylate was provided by Pfizer
Japan Inc. (Tokyo, Japan). Tolazoline hydrochloride was pur-
chased from Avocado Research Chemical, Co. (Lancashire,
England). Ergotamine tartrate and dihydroergotamine mesylate
were purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo,
Japan). Prazosin and bis-benzimide H33342 trihydrochloride
(Hoechst33342) were obtained from Wako Pure Chemical
Industries, Ltd. (Osaka, Japan), and terazosin hydrochrolide,
urapidil hydrochloride, naftopidil dihydrochloride, and mitoxan-
trone dihydrochloride, from Sigma-Aldrich Chemical, Co. (St
Louis, MO). 2-(4-Iodophenyl)-5-(2, 4-disulfophenyl)-2H-tetrazoli-
um, monosodium salt (WST-1) and 1-methoxy-5-methylphenazi-
nium methylsulfate were purchased from Dojindo Laboratories
(Kumamoto, Japan).
Cells and cell culture
HeLa cells [12] were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen, Corp., Carlsbad, CA) supplemented
with 10% heat-inactivated fetal bovine serum (lot. no. 99H2314 or
40K2368, Sigma-Aldrich) and 100 mg/L of kanamycin sulfate
(Invitrogen). Cells were seeded into culture flasks, grown in a
humidified atmosphere of 5%CO2–95% air at 37uC, and
subcultured with 0.05% trypsin-0.02% EDTA (Invitrogen).
HeLa/SN100 cells were established by continuous exposure to
SN-38 in our laboratory [12]. They were maintained in a similar
manner to HeLa cells, except that the DMEM contained 100 nM
SN-38. The number of passages for HeLa and HeLa/SN100 was
398–408 and 15–24, respectively.
WST-1 colorimetric assay
Effects of a-adrenoceptor antagonists on sensitivity to mitoxan-
trone in HeLa and HeLa/SN100 cells were evaluated with the
WST-1 assay [27]. Cells were seeded on 96-well plates and pre-
cultured for 24 h. The medium was exchanged for one containing
mitoxantrone at various concentrations with or without a-
adrenoceptor antagonists (ergotamine products: 1 nM, 10 nM or
100 nM; others: 0.1 mM, 1 mMo r1 0mM) (Figure 1), and then
cells were incubated for 72 h at 37uC. The culture medium was
replaced with a medium containing a WST-1 reagent, and 3 h
later, the absorbance in the well was determined at 450 nm with a
reference wavelength of 630 nm by using a microplate reader
(SpectraFluor
TM, Tecan, Switzerland). The 50% growth inhibito-
ry concentration (IC50) of the a-adrenoceptor antagonists or
mitoxantrone was estimated according to the sigmoid inhibitory
effect model, E=Emax6[12C
c/(C
c+IC50
c)], using the nonlinear
least-squares fitting method (Solver, MicrosoftH Excel). E and Emax
represent the surviving fraction (% of control) and its maximum,
respectively. C and c represent the concentration in the medium
and the sigmoidicity factor, respectively. Relative sensitivity was
defined by dividing the IC50 value for mitoxantrone in the control
by that in the groups treated with calcium antagonists.
Expression of ABCG2/BCRP mRNA by a real time RT-PCR
assay
HeLa/SN100 cells were seeded into 60-mm dishes and pre-
cultured for 24 h. The medium was exchanged for one containing
a-adrenoceptor antagonists (ergotamine products: 100 nM; others:
10 mM) and cells were incubated for 24 h. Then, total RNA
extracted from the cells with a GenElute
TM Mammalian Total
RNA Miniprep kit (Sigma-Aldrich). Total RNA (0.5 mg) was
reverse transcribed with a PrimeScript
TM RT reagent kit
Figure 2. mRNA levels of ABCG2/BCRP. HeLa/SN100 cells were incubated with medium containing a-adrenoceptor antagonists (ergot alkaloids:
100 nM; other a-adrenoceptor antagonists: 10 mM) for 24 h. Total RNA was extracted from the cells, and ABCG2/BCRP mRNA expression normalized
to b-actin mRNA expression was evaluated by quantitative real-time PCR. Each bar represents the mean 6 S.E. (n=3).
doi:10.1371/journal.pone.0030697.g002
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for 15 min and 85uC for 5 s as heat shock. The real-time
quantitative PCR assay was performed using the Applied
Biosystems 7500 Sequence detecting system (Applied Biosystems,
Foster City, CA), and SYBRH Premix Ex Taq
TM II (TakaraBio).
cDNA (20 ng per sample) was used to perform duplicate PCR
Figure 3. Cellular distribution of Hoehst33342. HeLa and HeLa/SN100 cells were precultured for 48 h in a humidified atmosphere containing
5% CO2 at 37uC. (A) HeLa and HeLa/SN100 cells were incubated with phenol red-free HBSS containing 3 mM of Hoechst33342, and images were
acquired at 0 and 15 min. (B) The effects of a-adrenoceptor antagonists at 10 mM (except for ergot alkaloids at 100 nM) for 15 min were
demonstrated in HeLa/SN100 cells.
doi:10.1371/journal.pone.0030697.g003
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BCRP-Forward; TGA CGG TGA GAG AAA ACT TAC,
ABCG2/BCRP-Reverse; TGC CAC TTT ATC CAG ACC T,
b-actin-Forward; TCA TGA AGT GTG ACG TGG ACA TC, b-
actin-Reverse; TGC ATC CTG TCG GCA ATG. The threshold
cycle (Ct) was used for determining the relative expression level of
each gene, by normalizing to the Ct of b-actin. The DDCt was
used to calculate the relative change. The equation for analyzing
ABCG2/BCRP expression was as follows: ABCG2/BCRP
level=2
2DCt, where DCt=Ct (ABCG2/BCRP)2Ct (b-actin). A
dissociation curve analysis was also performed at the end of the
amplification process, because SYBRH Green binding was not
sequence specific.
Fluorescent imaging
HeLa and HeLa/SN100 cells were seeded on a 35-mm glass-
bottom culture dish (Matsunami Glass Ind., Ltd. Osaka Japan),
and pre-cultured for 48 h in a humidified atmosphere of 5% CO2–
95% air at 37uC. Cells were washed twice with warmed Hanks’
balanced salt solution containing 25 mM HEPES (HBSS), and
incubated with 3 mM of Hoechst33342 in the absence or presence
of a-adrenoceptor antagonists (ergotamine products: 100 nM;
others: 10 mM) for 15 min at 37uC. Fluorescence micrographs
were acquired at 0 and 15 min using a confocal laser scanning
microscope (LSM510META Ver4.2, Carl Zeiss Co., Ltd,
Oberkochen Germany) with a blue diode for excitation (405 nm).
Transport experiments with Hoechst33342
In the accumulation experiments, HeLa and HeLa/SN100
cells were seeded on 24-well plates, and pre-cultured for 48 h in a
humidified atmosphere of 5% CO2–95% air at 37uC. The cells
were washed three times with warmed HBSS, and the
accumulation experiments were started with the addition of fresh
HBSS containing 3 mM Hoechst33342, a substrate for ABCG2/
BCRP, with or without a-adrenoceptor antagonists (ergotamine
products: 1 nM, 10 nM, or 100 nM; others: 0.1 mM, 1 mM, or
10 mM).
In the efflux experiments, HeLa and HeLa/SN100 cells were
pre-cultured as described for the accumulation experiments. Cells
were washed three times with warmed HBSS and pre-loaded
with the incubation medium in fresh HBSS containing 3 mM
Hoechst33342 with or without a-adrenoceptor antagonists
(ergotamine products: 100 nM; others: 10 mM) for 60 min. After
being loaded, HBSS was immediately removed and cells were
washed rapidly twice with ice-cold HBSS. Efflux experiments
were started with the addition of fresh warmed HBSS with or
without a-adrenoceptor antagonists (ergotamine products:
100 nM; others: 10 mM), and further incubated at 37uC. In both
experiments, the reaction was stopped at the desired times by
aspirating the HBSS from the well, followed by washing three
times with ice-cold phosphate-buffered saline (PBS). Then, cells
were lysed with PBS containing 0.1% Tween20H.A l i q u o t s
(100 mL) of the cell lysate were diluted twice and transferred to
Figure 4. Time course of accumulation of Hoechst33342. Cells were incubated with 3 mM Hoechst33342 in the absence (#) or presence of a-
adrenoceptor antagonists (ergot alkaloids: m, 1 nM; &, 10 nM; ¤, 100 nM, other a-adrenoceptor antagonists: m, 0.1 mM; &,1mM; ¤,1 0mM) for the
desired times at 37uC. Each point represents the mean 6 S.E. (n=3), and error bars are included in the symbols. * and ** p,0.05 and 0.01 significantly
different from the control at the corresponding time points, respectively.
doi:10.1371/journal.pone.0030697.g004
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Hoechst33342 was measured with an excitation wavelength of
340 nm and emission wavelength of 465 nm using Spectra-
Fluor
TM (Tecan). Protein content was determined by the Lowry
method [28] using bovine serum albumin (Sigma-Aldrich) as the
standard.
Flow cytometry
HeLa and HeLa/SN100 cells were seeded on 60-mm dishes
and pre-cultured for 24 h. The medium was exchanged for one
containing 50 nM mitoxantrone in the absence or presence of a-
adrenoceptor antagonists (ergotamine products: 100 nM; others:
10 mM), and cells were incubated for 8 h. Cells were trypsinized
and washed with ice-cold PBS, and fixed in 70% ethanol
containing PBS. The harvested cells were treated with propidium
iodide (PI) staining buffer containing RNase (Becton-Dickinson,
San Jose, CA, USA) for 15 min, and analyzed by a flow
cytometer (FACSCalibur HG
TM, Becton-Dickinson). PI was
detected with 488 nm excitation, and a 564–606 nm band pass
filter.
Figure 5. Time course of the efflux of Hoechst33342. Cells were incubated with 3 mM Hoechst33342 in the presence of 10 mMo fa-adrenoceptor
antagonists (100 nM for ergot alkaloids) for 60 min at 37uC, washed twice with ice-cold HBSS and incubated with warmed HBSS in the presence of
10 mMo fa-adrenoceptor antagonists (100 nM for ergot alkaloids)for the desired times. #, HeLa; N, HeLa/SN100; D, HeLa/SN100+10 mM a-adrenoceptor
antagonists (100 nM for ergot alkaloids). Each point represents the mean 6 S.E. (n=3), and error bars are included in the symbols. * and ** p,0.05 and
0.01 significantly different from the HeLa/SN100 cells in the absence of a-adrenoceptor antagonists at the corresponding time points, respectively.
doi:10.1371/journal.pone.0030697.g005
Table 2. Cell cycle profile of HeLa/SN100 cells treated with
mitoxantrone in the presence of a-adrenoceptor antagonists.
G0/G1 phase (%) S phase (%) G2/M phase (%)
Control 46.2 37.6 16.2
Doxazosin 35.0 43.7 21.3
Prazosin 30.1 48.9 21.0
Terazosin 40.3 41.4 18.3
Tolazoline 39.7 35.1 25.2
Naftopidil 35.0 40.3 24.7
Urapidil 36.5 39.9 23.6
Dihydroergotamine 43.7 37.8 18.5
Ergotamine 42.6 39.8 17.6
HeLa/SN100 cells were incubated with mitoxantrone for 8 hours in the absence
(Control)orpresenceofa-adrenoceptorantagonistsbeforebeingstainedwithpro-
pidiumiodide.DNAcontentwasanalyzedbyflow-cytometryandthepercentageof
cells in each phase of the cell cycle was obtained by using the Modfit program.
doi:10.1371/journal.pone.0030697.t002
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Comparisons were performed with a non-repeated one-way
analysis of variance followed by the Dunnett test for multiple
comparisons. A p value of less than 0.05 (two-tailed) was
considered significant.
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